Table II.

Double-blind trials examining selective serotonin reuptake inhibitor augmentation of antipsychotic agents in patients with schizophrenia^a

Study	n	Baseline depression	Medication	Duration (wk)	Results
Silver and Nassar[47]	30	Mean HDRS score 7.7 (placebo and fluvoxamine groups)	Fluvoxamine	7	No differences in HDRS Scores
Addington et al.[48]	48	Schizophrenia with major depression; mean HDRS score 20.6; mean CDRS score 14.0 (for both groups combined)	Sertraline	6	No difference in CDRS or HDRS scores
Buchanan et al.[49]	33	Mild-to-moderate depression; mean HDRS score 13.3 (fluoxetine), 12.6 (placebo)	Fluoxetine augmentation of clozapine	8	No difference in HDRS scores
Goff et al.[50]	41	Mild-to-moderate depressive symptoms; major depression excluded; mean HDRS score 13.9 (fluoxetine), 12.8 (placebo)	Fluoxetine augmentation of depot antipsychotic	6	No difference in HDRS scores
Spina et al.[51]	30	Mild-to-moderate depressive symptoms; mean HDRS score 11.5 (fluoxetine), 12.2 (placebo)	Fluoxetine	12	HDRS scores better in fluoxetine group
Salokangas et al.[52]	90	Not specified except that scores of ≥4 on PANSS P7 (hostility), N4 (passive apathetic withdrawal), G2 (anxiety) and G6 (depression) were required for inclusion	Citalopram	12	No depression outcomes assessed; improvement in CGI and subjective well- being, based on a visual analogue scale
Vartiainen et al.[46]	19	Not specified except that subjects were patients with schizophrenia and were excluded if their score on item 9 (depression) of the BPRS was >3	Citalopram	24	No depression outcomes assessed; lower frequency of aggressive incidents with citalopram

^aAll studies were double blind and placebo controlled except Vartiainen et al.,^[46] which was a double-blind, placebo-controlled, crossover study.

BPRS = Brief Psychiatric Rating Scale; CDRS = Calgary Depression Rating Scale; CGI = Clinical Global Impressions scale; HDRS = Hamilton Depression Rating Scale; PANSS = Positive and Negative Syndrome Scale.